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The X chromosome and X-linked variants have largely been ignored in genome-wide and candidate association
studies of infectious diseases due to the complexity of statistical analysis of the X chromosome. This exclusion is
significant, since the X chromosome contains a high density of immune-related genes and regulatory elements that
are extensively involved in both the innate and adaptive immune responses. Many diseases present with a clear sex
bias, and apart from the influence of sex hormones and socioeconomic and behavioural factors, the X
chromosome, X-linked genes and X chromosome inactivation mechanisms contribute to this difference. Females
are functional mosaics for X-linked genes due to X chromosome inactivation and this, combined with other X
chromosome inactivation mechanisms such as genes that escape silencing and skewed inactivation, could
contribute to an immunological advantage for females in many infections. In this review, we discuss the
involvement of the X chromosome and X inactivation in immunity and address its role in sexual dimorphism of
infectious diseases using tuberculosis susceptibility as an example, in which male sex bias is clear, yet not fully
explored.
Keywords: Tuberculosis, Sex bias, X chromosome, Host genetics, SusceptibilityIntroduction
The human sex chromosomes are genomic structures
that distinguish males and females on the chromo-
somal level. The XY sex-determination system is
present in humans, and females have two X chromo-
somes, while males have one Y and one X chromo-
some [1]. These chromosomes evolved approximately
180 million years ago from ordinary autosomes [2].
Recombination during male meiosis was suppressed,
over time, resulting in vast levels of divergence be-
tween the human sex chromosomes, with the excep-
tion of the pseudoautosomal regions (PAR1 and
PAR2) located at the termini of the X and Y chromo-
somes [3]. Over 800 protein coding and 600
non-coding genes are distributed over the nearly 155
million base pairs of the X chromosome [4]. Until* Correspondence: haiko@sun.ac.za
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from candidate gene and genome-wide association
studies (GWAS) due to the statistical complexity of
analysing and comparing the haploid male to diploid
female data, but analysis tools have now been devel-
oped to incorporate this chromosome.
Gao et al. [5] developed a toolset for X chromosome
data analysis and association studies that can be used
for quality control and analysis of X chromosome
GWAS data. Other software using genotyping data, but
not specifically focused on the X chromosome, have
also included the option to analyse X-linked genotypes.
PLINK version 1.9, a software to conduct association
testing using genotyping data, incorporated different
models to analyse the X chromosome [6]. Impute2 and
shapeit2 are programs designed to impute and phase
genotyping data respectively, and until recently, imput-
ation and phasing was not possible for the X chromo-
some thus excluding this chromosome from
downstream analyses [7, 8]. The ability to increase the
amount of genotyping data through imputation and in-
cluding the X chromosome in statistical analysis allows
for X-linked meta-analysis and could help elucidatele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ual’s genomic data to determine ancestry by comparing
allele frequencies to those of reference populations.
Until recently, this analysis was inaccurate for haploid
genotypes and thus overestimated X-linked ancestral
components in males. However, inclusion of
haploid-specific ancestry inference in the ADMIXTURE
v1.3.0 software now allows for X-linked global ancestry
inference [9]. These ancestral components can now be
included as covariates in X-linked association testing to
improve the quality of the results. The software RFMIX
also incorporated the option of assigning local ancestry
on the X chromosome [10], allowing the comparison of
autosomal and X-linked ancestral distributions, which
could indicate sex-biased admixture [11–13].
The development of these tools is especially signifi-
cant for diseases in which a sex bias is present. Human
males are more susceptible to many diseases, including
bacterial infections, while females are more likely to de-
velop autoimmunity [14]. This sex bias is not only due
to socioeconomic and behavioural factors, such as the
underreporting of female cases and/or access to health-
care, but may also in part be due to biological sex dif-
ferences as determined by the X chromosome and X
chromosome inactivation (XCI) [15]. XCI is the process
through which one X chromosome is inactivated to bal-
ance dosage of gene expression between XX females
and XY males. XCI is established early during embry-
onic development and is maintained almost indefinitely.
As males are haploid for the X chromosome, it has
been suggested that any damaging genetic variants on
the X chromosome will have a more pronounced im-
munological consequence in males than in females,
thereby introducing sex-based differences and influen-
cing the sex bias of a disease. In contrast, females, who
are functional mosaics for X-linked genes, may have
less-severe consequences, further compounded by the
process of skewed XCI and genes escaping silencing
[16]. This review will focus on the involvement of the X
chromosome and XCI in immunity and will address
sexual dimorphism in infectious diseases using tubercu-
losis (TB) susceptibility as an example, in which sex
bias is clear, yet not fully explored.
X chromosome, the immune system and sex
hormones
Many X-linked genes are involved in the innate and
adaptive immune system [17]. This includes pattern rec-
ognition receptors (PRRs) such as toll-like receptor
(TLR) 7 and TLR8 as well as IRAK1, a key regulatory
molecule in the TLR-dependent signalling pathway [18].
A number of transcriptional and translational control ef-
fectors functioning downstream of activated cytokine re-
ceptors are also located on the X chromosome [19]. Forexample, NF-kB essential modulator (NEMO) modulates
NF-kB expression, a transcription regulator that is in-
volved in multiple immune pathways [20]. Furthermore,
it is not only X-linked genes that could influence the sex
bias, but also X-linked control mechanisms like
non-coding micro RNA (miRNA). The X chromosome
contains approximately 10% of the total genomic
miRNA [21], which is involved in the regulation of gene
expression by supressing mRNA translation or triggering
mRNA degradation. Locations of immune-related genes
and key miRNA regions are indicated in Fig. 1.
The androgen receptor, a sex hormone receptor that in-
hibits antibody production, is also coded on the X
chromosome, showing that even the effect of sex hor-
mones can be amplified by the X-linked sex hormone re-
ceptor genes [19]. Sex hormones are involved in the
immune response, and multiple immune-related cells, in-
cluding T cells, B cells, natural killer cells, macrophages
and dendritic cells, express estrogen receptors (ER-alpha
and ER-beta), indicating that immune-related cells are
partly controlled by the female sex steroid hormone estro-
gen [19, 22, 23]. In humans, it is evident that females have
increased resistance against microbial infections, which
suggests that females have a more vigorous immune de-
fence against most invading pathogens [24–27]. Females
also have higher antibody responses and more adverse re-
actions in response to a number of vaccines [19]. Estrogen
acts as an immune activator while testosterone acts as an
immune suppressor [19, 28]. Testosterone has been
shown to have an inhibitory effect on the immune system
through upregulation of anti-inflammatory cytokines
(IL-10), while estrogen enhances the immune system by
upregulating pro-inflammatory cytokines (TNFα). In
line with these hormone functions, it has been ob-
served that for some diseases the male bias becomes
apparent only after sexual maturation (ages 15–16
years) and female progression to disease and mortality
rates are altered during their reproductive years [29].
However, sex-based differences in immune responses
exist between pre-pubertal girls and boys as well as
post-menopausal women and elderly men, indicating
that sex bias is present without the involvement of
hormones [19]. These differences could be attributed
to the complexity of studying the impact of hormones
on disease susceptibility while using different experi-
mental designs between studies [14]. Sex hormones
also vary with age and physiological state of the indi-
vidual and can regulate transcription of many genes
involved in the development and maturation of im-
mune cells. They also influence the regulation and
modulation of the immune response and immune signal-
ling pathways [30]. Although both sex-hormones and the X
chromosome affect the immune system, the effects of these
two factors are likely independent of each other [14].
Fig. 1 Illustration of the X chromosome indicating the five different strata and chances of genes escaping inactivation within each stratum.
Regions lined in red contain the highest densities of immune-associated genes while genes discussed in this review are indicated in green.
Genes that contain intragenic miRNA are indicated in black followed by the miRNA number. XIC: X chromosome inactivation centre containing
XIST and XACT genes; PAR: Pseudoautosomal region; TLR8: Toll-like receptor 8; TLR7: Toll-like receptor 7; CYBB: Cytochrome b-245, beta
polypeptide; AR: Androgen receptor; CXCR3: C–X–C motif chemokine receptor 3; TNFS5: Encodes CD40 ligand; NEMO: NF-kB essential modulator;
IRAK1: Interleukin-1 receptor associated kinase 1; HUWE1: HECT, UBA & WWE domain containing 1; GABRA3: Gamma-aminobutyric acid A receptor
subunit alpha 3
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Females carry both a maternal and paternal X chromo-
some, while males carry only a maternal copy. In order
to regulate dosage expression of X-linked genes, one X
chromosome is inactivated in females, resulting in them
being functional mosaics for X-linked genes [21]. XCI is
initiated in early foetal development and either the ma-
ternal or paternal X chromosome is randomly silenced
in XX cells. This is maintained through epigenetic
mechanisms in subsequent cellular divisions to ensure
balanced expression X-linked genes in females [31].
XCI developed as a response to gene loss in the Y
chromosome during the evolutionary development of
the human sex chromosomes [3]. Mammalian sex chro-
mosomes developed from a pair of autosomes approxi-
mately 300 million years ago [32]. Several large-scale
chromosomal inversions on the Y chromosome led to
disruption of homology between the sex chromosomes,
suppressing recombination and resulting in Y chromo-
somal gene loss in the inverted chromosomal region [3].
These inversions on the Y chromosome are referred to
as strata as indicated in Fig. 1. Following gene loss onthe Y chromosome X-linked gene expression needed to
be increased in males to control the dosage of gene ex-
pression from the single X chromosome. In females, up-
regulation of X-linked genes would disrupt dosage
compensation as they have two X chromosomes and as
a result one X chromosome is inactivated. However,
gene expression is upregulated on the active X chromo-
some in order to regulate dosage [33, 34]. XCI is a vital
mechanism in females as many X-linked genes are ex-
tremely dosage sensitive and any disruption of the dos-
age compensation mechanism could have severe
developmental and health consequences [33].
Mary Lyon first proposed the XCI hypothesis based on
her observations in mice [35], and since then, significant
progress has been made in elucidating the XCI mechan-
ism in mice. The XCI mechanism in humans is still un-
clear and beyond the scope of this review but discussed
elsewhere [33, 36–42]. Briefly, human XCI is thought to
be controlled by the X inactivation centre (XIC), an
X-linked locus located at Xq13 (Fig. 1) and containing
multiple protein and RNA coding genes potentially in-
volved in the XCI mechanism [43]. The two main long
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tion specific transcript (XIST), responsible for silencing,
and the X active specific transcript (XACT) which keeps
the X chromosome active [44–47]. The exact mecha-
nisms of how these lncRNAs determine the state of a X
chromosome is still unclear, and it has also been pro-
posed that a third regulatory element, potentially coded
by a gene on chromosome 19, is also involved in the
XCI process [33]. Hypotheses about the lncRNAs as well
as an autosomal regulatory element are discussed in de-
tail elsewhere [33, 43, 48–51]. While the exact mecha-
nisms are unclear, the importance of these lncRNAs has
been validated as single nucleotide polymorphisms
(SNPs) or mutations in the XIC can have severe effects
on XCI, by disrupting dosage compensation, which
could impact on female development and health [33,
52]. In fact, evidence of the effect of XCI can be seen in
tumorigenesis and noncongenital diseases, where loss of
XCI control has led to tissue instability and decreased
defence against diseases [53–55], including autoimmune
diseases [56].
While disruption of XCI could be detrimental to fe-
males as it disrupts dosage compensation, the mosaic
nature as a result of XCI could give them a distinct ad-
vantage over males [14, 37]. Deleterious X-linked muta-
tions have large effects and could lead to death or
disease in males due to them being haploid for X-linked
genes. In females, however, random inactivation leads to
a mosaic makeup where about half of the cell population
expresses the mutant allele while the other half ex-
presses the wild type allele. This heterozygous expres-
sion means the wild type allele can compensate for the
mutant allele and lessen the impact or penetrance of this
allele in females compared to males [33]. This mosaic
advantage in heterozygous females can be further com-
pounded by non-random or skewed inactivation and
genes that escape silencing.
Escaping X inactivation and skewed or
non-random inactivation
While the XCI process in humans is not yet fully under-
stood, studies of human aneuploidy indicate that in a
diploid human cell there is always just one active X
chromosome in either sex [33, 37]. In Turner syndrome,
individuals have only one sex chromosome (one X
chromosome, X0) which is kept active, while in males
with Klinefelter syndrome (XXY) one X chromosome is
silenced [33]. This suggests that the human XCI mecha-
nisms protect one X chromosome while inactivating all
others.
However, some X-linked genes have Y homologues
(most of them situated on the distal end of Xp and PAR
regions) and thus two copies are present in males and
females. To maintain dosage balance between the sexes,these XY genes escape silencing. Most genes that escape
silencing are located in the Xp region and are often de-
pleted in repressive marks associated with XCI and
enriched for markers associated with active gene tran-
scription [57]. These regions that escape inactivation
carry features associated with active chromatin [58]. This
suggests that genes that escape silencing are subjected to
a regional bias, which correlates with the theory that dis-
tal genes in younger strata (regions on the X chromo-
some that differentiated from the Y chromosome last
and contain more XY genes than older strata) have a
higher chance of escaping inactivation.
More recent evidence extrapolated on the idea of re-
gional bias in escape from inactivation and showed that
the chance of genes escaping silencing is also dependent
on a gene to gene-specific bias [32]. This is supported by
the fact that approximately 15–20% of X-linked genes
outside of PAR also escape silencing even though they
are subject to less regional bias. Naqvi et al. [32] classi-
fied X-linked genes into three classes, namely X-linked
genes with a surviving homologue (class 1) and X-linked
genes without a surviving homologue that are either
subject to XCI (class 2) or escape silencing (class 3) [32].
These three classes of X-linked genes differ based on
dosage sensitivities. Class 1 genes were most dosage sen-
sitive and expression required strict regulation, while
class 2 genes had intermediate dosage sensitivity while
class 3 genes that escaped silencing had the lowest dos-
age sensitivity [32]. This suggests that genes that escape
silencing are subjected to regional bias and the chance
of escape depends on the sensitivity of that gene to
changes in dosage. While defects in the XCI mechanism
could disrupt the XCI pattern of dosage-sensitive genes
and be detrimental to the health and development of fe-
males, genes that are less sensitive to dosage could es-
cape resulting in altered gene expression between the
sexes and potentially contribute towards a sex-specific
phenotype, which could contribute to sex biases in dis-
ease susceptibility [14, 17, 59].
Random inactivation ideally leads to a balanced mosaic
of X-linked genes in females. However, this balance can
be disrupted, especially in heterozygous females carrying
deleterious mutations on one or both X chromosomes,
or if the XCI mechanism is defective, leading to a
skewed inactivation pattern. Skewed inactivation is the
process by which one X chromosome is preferentially si-
lenced in over 75% of cells. If a cell has a deleterious
mutation on the active X chromosome, it could alter the
viability of the cell and even lead to cell death, suggest-
ing that these mutations could lead to positive or nega-
tive selection of a specific active X chromosome [60, 61].
The extent of this selection pressure is correlated with
three factors. Firstly, the viability of the cell which will
be determined by the active X chromosome. If cells with
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then only cells with the viable gene will propagate. This
depends on the type of mutation (synonymous or
non-synonymous) and its effect on gene function. Sec-
ond, the gene function can influence the skewing if it is
tissue-specific while a constitutively expressed gene
could affect the skewing on a global scale. Finally, genes
escaping inactivation can also influence selection as they
will influence the penetrance of the mutated gene [62].
While cell viability combined with XCI can skew inacti-
vation patterns, other aspects can also lead to
non-random inactivation. Defects in the XCI mechanism
can also lead to skewed inactivation and SNPs in the
XIST gene correlates with skewing. Plenge et al. [52]
showed that skewed inactivation profiles in multiple fe-
males occurred due to a C to G transversion in the pro-
moter region of the XIST gene [52]. However, some
females with this transversion still had nearly random
inactivation suggesting that the transversion alone is not
enough to skew inactivation and some other defect com-
pounding the effects is likely present as well.
Other factors that can result in skewed inactivation
are reduced number of embryonic cells at the onset of
XCI and age. The lower the number of cells at the onset
of XCI, the higher the chance of observing non-random
inactivation and any bottleneck during development that
limits the number of cells can lead to skewed inactiva-
tion [62]. Age has also been correlated with degree of
skewing which seems to increase in older women [63–
66]. The exact reason why skewing increases with age is
unclear, but it could be as a result of stochastic loss and
genetic selection of subtle SNPs, gradually increasing
their penetrance over time due to increased skewing in
the XCI pattern [63, 64, 67, 68]. The causes of skewedTable 1 Sex bias of selected bacterial, fungal, parasitic and viral infe
Infection Organism Disease
Bacterial Treponema pallidum Syphilis





Fungal Cryptococcus neoformans Fungal m
Candida albicans Onycho




Viral Influenza A Influenz
Hepatitis C HepatitiXCI discussed here suggest that this process is genetic-
ally determined [60] and can give females an advantage
by protecting them from deleterious mutations and their
effects. However, skewed inactivation patterns have also
been observed in numerous tumours and cancer types
[57, 69]. This suggests that the combined impact of XCI,
genes that escape silencing and skewing can lead to
sex-specific phenotypes and potentially affect disease
and developmental bias between the sexes.
X chromosome and infectious disease
susceptibility
It is well documented that females have a stronger in-
nate and humoral immune response than males and are
thus less susceptible to many bacterial, fungal, parasitic
and viral infections, while being more prone to develop-
ing an autoimmune disease or malignancies (Table 1,
[25]). However, as not every microorganism elicits a
sex-differentiated response, it has been proposed that
the invading organisms and how they interact with the
host are important contributing factors to whether or
not the host immune response will differ between the
sexes [70].
Many infections exhibit sex-biased incidence rates and
many of them present with a male bias (Table 1). While
age and sex hormones contribute, as in the case of Lyme
disease and hepatitis, these factors do not fully account
for this [71–74]. This suggests that the X chromosome
and XCI may contribute to this bias. Supporting evi-
dence from this can be taken from the mouse four core
genotype (FCG) model. In this model, the sex chromo-
some complement of the mice (XX or XY) does not re-
late to the gonadal sex, allowing for both XX males and
females as well as XY males and females [75]. Thisctions
Bias Reference
Male [103–105]




mias Female [107, 108]
eningitis Male [109–111]
mycosis Female [112–117]





s Male [73, 74]
Schurz et al. Human Genomics            (2019) 13:2 Page 6 of 12allows the study of the phenotypic effect based on sex
complement, with and without the influence of sex hor-
mones. Studies using the FCG model have identified dif-
ferences in behaviour, gene expression and disease
susceptibility that were solely due to sex chromosome
complement and independent of sex hormones [75].
While the FCG is only a model, it can still provide
useful information and shows that sex chromosome
complement, X-linked genes and XCI can severely im-
pact sex differences in phenotype. Recent studies in fe-
male T and B cells could explain the enhanced female
immune response to infection. XCI in female lympho-
cytes is predisposed to become partially reactivated,
allowing genes to escape silencing leading to overexpres-
sion of immune-related genes [49, 76]. Female T cells
had biallelic expression of CD40LG, CXCR3 and TLR7.
The same was observed for B cells where biallelic ex-
pression and increased transcription of X-linked
immune-related genes was observed [76]. Furthermore,
in both T and B cells, the XIST RNA pattern was dis-
persed and the inactivated X chromosome lacked typical
heterochromatic modifications usually associated with
the inactive X chromosome [76].
These studies in female lymphocytes provide mechan-
istic evidence for enhanced female immunity to infec-
tious diseases and the involvement of X-linked genes
and XCI. The enhanced immune response and increased
expression of immune-related genes could also explain
why females are more prone to developing autoimmune
disorders [14, 25, 76].
X chromosome and tuberculosis
TB, caused by the bacterium Mycobacterium tubercu-
losis, is the leading cause of death due to a single infec-
tious agent worldwide. Approximately one quarter of the
world’s population is infected with the bacterium, but
only 5–15% will develop active TB [77]. The severity of
this pandemic is exacerbated by the emergence of
multidrug-resistant and extensively drug-resistant (MDR
and XDR) M. tuberculosis strains. Although vital to the
affected individual, it is clear that antimycobacterial
treatment alone will not eradicate this disease.
Host-directed therapy is emerging as a complementary
approach to reduce the global TB burden, but will re-
quire an improved understanding of the host immune
response and the genetic mechanisms that underlie it
[78]. To date, variants of genes involved in both the in-
nate and adaptive immune responses have been associ-
ated with TB (reviewed by [79]). However, these
investigations have been largely aimed at the autosome,
while excluding the X chromosome. Given the high
density of immune-related genes on the X chromosome
[19] and the fact that TB presents with a clear sex bias
across populations, this is a serious oversight [80].In most countries, the TB notification rate is twice as
high in HIV-negative males than in HIV-negative fe-
males [80]. This ratio ranged from 1.56 to 2.73 and while
it differs between countries, it was clear that more men
than women are affected regardless of ethnicity or geo-
graphical location. Epidemiological data has shown that
males and females differ in infection prevalence, varying
rates of progression, differences in incidence of clinical
disease and mortality rates due to TB [81]. The cause of
this male sex bias is not fully understood, but may in-
clude socioeconomic and behavioural factors, such as
the underreporting of female cases and/or access to
healthcare [23, 82–84]. However, these differences in
case reporting may influence the bias but cannot explain
the consistent global trend for male bias in TB [22]. In a
large meta-analysis including 29 surveys from 14 coun-
tries, a strong male bias was found in both TB notifica-
tions and prevalence and it was concluded that access to
healthcare is not a confounding factor. This was repli-
cated by Salim et al. [82] who conducted a survey of
223,936 individuals in Bangladesh and identified 7001
TB suspects at a female to male ratio of 0.52:1. Sputum
was obtained from these individuals and 64 positive TB
cases were identified at a female to male ratio of 0.33:1.
These observed ratios did not differ much and were in
fact lower than the female to male ratio observed
through diagnosis in clinics which stood at 0.42:1. The
authors concluded that reduced access of women to
health care facilities does not significantly influence the
bias seen [82]. In a study conducted in Syria, men and
women did not have different knowledge or attitudes to-
wards TB, but women reported more barriers to seeking
health care. They were more likely to comply with treat-
ment and had higher treatment success rates compared
to men which could influence the bias when it comes to
TB mortality [85]. Furthermore, men seem to engage in
more “high risk” TB activities, including travelling,
smoking, going to bars and hazardous careers (e.g. min-
ing) [22]. In high-burden countries, more men than
women engage in smoking and it has been suggested
that smoking may explain up to one third of the gender
bias observed in TB [86]. Alcohol consumption could
have a similar effect. However, other risk factors, specif-
ically HIV infection and proximity to household con-
tacts, appear to have a female bias, which suggests that
although behaviour may influence the bias it is not suffi-
cient to fully explain the existing sex bias in TB [22].
Another contributing factor may be the influence of sex
hormones on the immune system (discussed in section “X
chromosome, the immune system and sex hormones”).
Females have been shown to have a more robust im-
mune system (as described in section “X chromosome
and infectious disease susceptibility”), and this is in part
mediated by sex hormones that control development
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neutrophils) involved in combating TB. Type 1 T helper
cells (Th1) are affected differently by male and female
sex hormones. Testosterone upregulates IL-10 while
downregulating IFN-γ [83] and estrogen increases
IFN-γ, TNFα and IL-12 production while supressing
production of IL-10 [84]. Macrophages, which play a
central role in controlling TB through active killing of
mycobacteria, are also influenced by sex hormones. The
female hormone estradiol has been shown to enhance
macrophage activation [29], while testosterone downre-
gulates macrophage activation by decreasing expression
of TLR4, a vital receptor for detecting M. tuberculosis
and initiating the innate immune response [24]. Neutro-
phils have recently garnered interest with regard to their
role in protection against TB and have been proposed to
be the predominantly infected phagocytic cell type in
pulmonary tuberculosis (pTB) [87]. Neutrophil recruit-
ment to areas of infection needs to be balanced as
under- and over-recruitment of neutrophils can have a
detrimental effect on tissue pathology [88]. In response
to trauma, testosterone decreases neutrophil activation
while estrogen increases it, but the effect of this on TB
is unknown and requires further investigation [89]. As
neutrophil recruitment needs to be balanced to avoid
under- or over-recruitment to sites of infection, it stands
to reason that the regulation of this recruiting mechan-
ism is of vital importance. In fact, miRNA-223 (Xq12,
Fig. 1), previously identified to be involved in the im-
mune response by Pinheiro et al. [90], can limit recruit-
ment of neutrophils by downregulating chemokine (C–
X–C motif ) ligand 2 (CXCL2) and chemokine (C–C
motif ) ligand 3 (CCL3). Mice with a miRNA-223 knock-
out were more susceptible to M. tuberculosis, due to ex-
cessive neutrophil accumulation in the lungs which
subsequently led to tissue damage [91]. Given that
miRNA-233 is X-linked, is subject to the effects of
skewed inactivation or may escape silencing, it could be
differentially expressed between males and females. Up-
regulation due to escape from silencing or preferential
expression of one gene copy due to skewed inactivation
could downregulate recruitment and thus the patho-
logical accumulation of neutrophils leading to a sex bias
in TB susceptibility. Clearly, these factors do not fully
explain the male bias associated with TB disease devel-
opment, suggesting that the host genotype, specifically
the X chromosome, may also contribute.
The third possible reason for the sex bias in TB sus-
ceptibility is linked to the X chromosome where skewed
inactivation or genes escaping silencing could give
females an enhanced immune response against M. tuber-
culosis. Some of the earliest evidence of this X-linked
genetic contribution to sex bias in TB susceptibility
came from the “Lübeck Disaster” in 1929. BacillusCalmette–Guérin (BCG) vaccine accidentally contami-
nated with M. tuberculosis was administered to 251 neo-
nates. One hundred seventy-three of these children
developed signs of active TB but recovered, while 72
died, and during follow-up, male children were more
likely to have poor outcomes than females [92]. Evidence
from studies of Mendelian susceptibility to mycobacter-
ial disease (MSMD) also supports the influence of the X
chromosome to disease susceptibility. MSMD is a rare
congenital syndrome that results in the predisposition to
diseases caused by non-virulent mycobacteria, BCG vac-
cines and environmental mycobacteria known not to be
disease causing in humans [93]. MSMD is classified into
two types, where autosomal MSMD is linked to defects
in five autosomal genes (IFNGR1, IFNGR2, STAT1,
IL12RB1 and IL12B) involved in the interleukin 12/23
dependant interferon γ (IFN-γ)-mediated immune re-
sponse [94]. On the other hand, X-linked recessive
(XR)-MSMD is less well understood [20]. Several genetic
defects have been proposed to cause XR-MSMD, and based
on the genes involved, XR-MSMD can be further subdi-
vided into two types, XR-MSMD type 1 and XR-MSMD
type 2. Type 1 XR-MSMD is caused by mutations in the
leucine zipper domain of the NF-kB essential modulator
(NEMO) gene, which selectively impairs the CD40 and
NF-kB/c-Rel-mediated induction of IL-12 production by
monocytes and monocyte-derived dendritic cells [93]. Pre-
disposition of type 2 XR-MSMD is increased by mutations
in two regions on the X chromosome, Xp11.4-Xp21.2 (129
known genes) and Xq25-Xq26.3 (70 known genes). These
regions may cause XR-MSMD independent of NEMO, and
Bustamante et al. proposed that variants in the cytochrome
b-245 beta polypeptide (CYBB) gene could predispose to
XR-MSMD-2 due to their selective effect on macrophages.
CYBB encodes the gp91 protein, which is an essential com-
ponent of the NADPH oxidase complex and severely af-
fects respiratory burst in macrophages, thereby impeding
their function and predisposing to XR-MSMD-2. NEMO
and CYBB are both X-linked genes that affect immune-
related cells and as such can alter susceptibility to TB.
XR-MSMD, like TB, shows a sex bias and affects more
males than females which can be attributed to females car-
rying two X chromosomes. If one of the X chromosomes
carries a defective NEMO or CYBB gene, random XCI can
result in the functional gene product still being expressed
and reducing the risk of disease. Skewed inactivation or
escape from silencing could further increase the
observed sex bias as NEMO and CYBB have a low
(stratum S1) and high (stratum S4) chance of escap-
ing inactivation (Fig. 1). However, TB in immunocom-
petent individuals is a multigenic disease linked to
variants in multiple genes that have a cumulative
effect on disease susceptibility and is even further
complicated by gene-gene interactions.
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bility identified the chromosome Xq26 region as con-
taining susceptibility genes, but did not specifically
investigate sex bias [95]. Although no specific genes
could be identified, the CD40 ligand encoded by the
TNFSF5 gene at Xq26.3 showed promise (Fig. 1), but re-
quires further investigation [95]. A study by Campbell
et al. [96] on 121 TB cases and their parents identified a
TNFSF5 (a CD40 ligand) variant (− 726) to be associated
with TB susceptibility in males. However, they failed to
replicate this association in a West African cohort of
1200 individuals.
More recently, sex-specific associations with genetic
variants in the X-linked toll-like receptor (TLR) 8 gene
(Table 2), which encodes a pattern recognition receptor,
were identified [97–102]. Davila et al. [98] identified four
variants in TLR8 (rs3764879, rs3788935, rs3761624 andTable 2 TLR8 association studies from different populations
Study Cohort Case Control S
















Hashemi-Shahri et al. [100] Iran 77 62 r
196 166 r
Bukhari et al. [101] Pakistan 45 22 r
58 65 r






Lai et al. [102] Chinese 96 146 r
40 97 r
OR odds ratio; 95% CI 95% confidence intervalrs3764880) that were significantly associated with TB sus-
ceptibility in Indonesian males, but not females. These
findings were validated in a male only cohort from Russia
and all four variants were again significantly associated
with TB susceptibility in males. A second study conducted
in a paediatric Turkish cohort showed a significant associ-
ation between rs3764880 and TB susceptibility in males
but not females and rs3764879 showed no significant as-
sociation in this cohort [99]. Hashemi-Shahri et al. [100]
also investigated the influence of rs3764880 on TB suscep-
tibility in a cohort from Iran but found no association in
either males or females. Significant associations were
found for both males and females in a Pakistani cohort for
rs3764880, but males were more strongly associated (p =
0.0013 for females and p < 0.0001 for males) [101]. Salie
et al. [97] was the first to identify an association between
rs3761624 and TB disease in females only (p < 0.001 forNP Allele Gender OR* 95% CI* P value
s3764879 C Male 1.9 1.2–2.7 0.012
s3764879 C Female 1.1 0.8–1.7 0.44
s3761624 A Male 1.8 1.2–2.8 0.007
s3761624 A Female 1.1 0.8–1.7 0.44
s3788935 A Male 1.8 1.2–2.7 0.017
s3788935 A Female 1.1 0.8–1.7 0.44
s3764880 A Male 1.8 1.2–2.9 0.007
s3764880 A Female 1.1 0.8–1.7 0.44
s3764879 C Male 1.2 1.02–1.48 0.03
s3788935 A Male 1.2 1.02–1.48 0.03
s3761624 A Male 1.2 1.01–1.46 0.04
s3764880 A Male 1.2 1.02–1.48 0.03
s3764880 A Male 0.43 0.16–0.72 0.007
s3764880 A Female NS NS NS
s3764879 C Male NS NS NS
s3764879 C Female NS NS NS
s3764880 G Male 1.15 0.84–1.59 0.80
s3764880 G Female 1.15 0.75–1.75 0.51
s3764880 A Male / / < 0.0001
s3764880 A Female 0.363 0.199–0.660 0.0013
s3761624 A Male / / 0.164
s3761624 A Female 1.54 1.19–1.99 < 0.001
s3764879 C Male 0.72 0.55–0.93 0.013
s3764879 C Female 1.41 1.08–1.83 0.011
s3764880 A Male 0.75 0.57–0.98 0.036
s3764880 A Female 1.42 1.09–1.87 0.011
s3764879 C Male 4.04 1.82–8.99 < 0.001
s3764879 C Female 5.05 0.44–57.38 0.191
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rs3764879 and rs3764880, were also investigated in this
South African Coloured (SAC) population and were sig-
nificantly associated in both males and females, but with
opposite effects. Finally, Lai et al. [102] showed that
rs3764879 was significantly associated with TB in males
but not females. The conflicting results of these studies in-
vestigating TLR8 may be explained by cohort size, ethni-
city, M. tuberculosis strain and environmental factors.
It is clear that the X chromosome and XCI (section “X
chromosome and infectious disease susceptibility”) is
significantly involved in TB susceptibility and the male
sex bias and future studies will need to focus on eluci-
dating these effects. Fully understanding the sex-biased
nature of TB will allow for medication tailored to a spe-
cific sex, which could improve treatment outcome, de-
crease the global TB burden and stem the tide of
emerging drug-resistant M. tuberculosis strains.
Discussion and concluding remarks
It is clear that sex-specific effects contribute to infec-
tious disease susceptibility and females have a major im-
munological advantage over males. Understanding the
origin of sex bias could guide treatment by allowing
sex-specific diagnostic and treatment regimes, thereby
decreasing time to initiation of treatment as well as in-
creasing treatment success of diseases with sex differ-
ences. The X chromosome may contribute to the
missing heritability or contain biomarkers that could be
used as diagnostic tools. As analytical tools are now
available to fully include the X chromosome in genetic
analyses, it is clear that the X chromosome should not
be ignored. Importantly, due to the haploid nature of
males, the power to detect a significant association will
be halved when compared to a female cohort of similar
size and this could have an effect on the results of
sex-stratified analysis. Thus, care must be taken when
analysing results, and a non-significant association in
one sex does not imply that that specific sex is not af-
fected by the variant, but could simply be as a result of
insufficient power to detect a sex-specific association.
While socioeconomic and behavioural factors as well
as sex hormones do influence sex bias, these factors do
not fully account for it, which leads to the conclusion
that the X chromosome itself is likely to greatly influ-
ence the immune response and sex bias in disease sus-
ceptibility. The X chromosome contains multiple
immune-related genes and immune regulatory elements
as well as the XIC that regulates X chromosome inacti-
vation. It is therefore clear that the X chromosome is in-
volved in the immune response and genes that escape
inactivation or are preferentially inactivated could influ-
ence the dosage of X-linked gene expression between
the sexes and as such could further influence the sexbias in disease. It is thus of vital importance that the
XCI mechanisms be further investigated to understand
all the regulatory elements involved and the contribution
to sex bias. Furthermore, the role of the X chromosome
in the innate and adaptive immune response should be
extensively investigated to determine how it contributes
and differs between the sexes. Elucidating the function
of the X chromosome and including it in biological stud-
ies and analyses could improve the understanding of
complex diseases such as TB.
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